ATLL
Summary
Adult T-cell Leukemia/Lymphoma (ATLL) is an aggressive malignancy of mature CD4+ T-cells caused by infection with Human T-lymphotropic virus type 1 (HTLV-1). It is endemic in regions like Japan, the Caribbean, and parts of Africa, and transmission occurs via sexual contact, blood products, breastfeeding, or IV drug use. Classic clinical findings include hypercalcemia, lytic bone lesions, lymphadenopathy, hepatosplenomegaly, skin lesions, and characteristic 'flower cells' (multilobulated lymphocytes) on peripheral smear.
Detail
ATLL pathophysiology centers on HTLV-1, a retrovirus that integrates into the host genome and transforms CD4+ T-cells via the viral protein Tax, which activates NF-κB and promotes uncontrolled T-cell proliferation while inhibiting tumor suppressor pathways (p53) and DNA repair mechanisms. The long latency period (decades) explains why only a small percentage (~5%) of HTLV-1 carriers develop ATLL, typically in adulthood.
Clinical subtypes include acute (most common, aggressive with leukemic involvement), lymphomatous (primarily nodal), chronic, and smoldering forms, with prognosis varying significantly. The acute and lymphomatous forms are aggressive with poor prognosis (median survival often <1 year) due to chemotherapy resistance and HTLV-1-associated immunosuppression.
Key clinical/lab findings: - Hypercalcemia (due to PTHrP-like cytokine production and osteoclast-activating factors) with lytic bone lesions - Peripheral blood smear showing 'flower cells' — lymphocytes with multilobulated, cloverleaf-shaped nuclei - Generalized lymphadenopathy, hepatosplenomegaly - Skin involvement (papules, nodules, erythroderma) - Immunosuppression predisposing to opportunistic infections (e.g., Strongyloides hyperinfection, Pneumocystis) - CD4+/CD25+ (IL-2 receptor) positive T-cells on flow cytometry
Diagnosis requires serologic/PCR confirmation of HTLV-1 infection combined with characteristic clinical and pathologic features. Treatment options include combination chemotherapy, antiretroviral therapy (zidovudine) plus interferon-alpha, and allogeneic stem cell transplant in eligible patients; however, outcomes remain poor for aggressive subtypes.
High-yield board associations: HTLV-1 is also linked to HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Differentiate from HTLV-2 (less clearly oncogenic) and from other T-cell lymphomas. Remember the mnemonic 'HTLV-1 causes ATLL' — hypercalcemia + lytic lesions + flower cells + endemic geography (Japan/Caribbean) is a classic USMLE vignette.
Sources
- First Aid for the USMLE Step 1
- Robbins and Cotran Pathologic Basis of Disease
- Goldman-Cecil Medicine
- UpToDate: Clinical manifestations of adult T-cell leukemia-lymphoma
Reviewed by Medusa editorial — medical student review. Information here is for study reference only and is not medical advice. Spotted an error? Let us know.